证券代码：002864 证券简称：盘龙药业 公告编号：2025-047 陕西盘龙药业集团股份有限公司 二、药品的其他相关情况 洛索洛芬钠凝胶贴膏（PLJT - 001），为治疗骨关节炎、肌肉痛、外伤后的 肿胀或疼痛的凝胶贴膏。PLJT - 001 中有效成分为洛索洛芬钠，苯丙酸类非甾体 抗炎药，具有显著的抗炎镇痛作用，尤其是镇痛作用较强。其作用机理为抑制前 列腺素合成，作用点为环化酶。洛索洛芬钠为前体药物，经皮肤吸收后，转变为 1 产品名称 洛索洛芬钠凝胶贴膏 规 格 每贴（14cm×10cm）含膏体 10g，含洛索洛芬钠 100mg（以 C15H17NaO3 计） 注册分类 化学药品 4 类 受理号 CYHS2503515 申请人 陕西盘龙药业集团股份有限公司 申请事项 境内生产药品注册上市许可 结论 根据《中华人民共和国行政许可法》第三十二条的规定，经审 查，决定予以受理。 一、药品相关情况 活性代谢物反式 - OH 体发挥作用。该凝胶贴膏具有低刺激过敏性，粘附力强不 易脱落，剂型轻薄且皮肤延展性好，可贴敷于活动关节，不影响日常活动，大幅 提升用药舒适度与便利性。 三、对公司的影响及风险提示 关于 PLJ ...

Core Viewpoint - The company, Panlong Pharmaceutical, has received a notice from the National Medical Products Administration regarding the acceptance of its application for the marketing authorization of the generic drug, Loxoprofen Sodium Gel Patch, which is intended for treating osteoarthritis, muscle pain, and swelling or pain after injuries [1] Group 1 - The product is a gel patch with significant anti-inflammatory and analgesic effects [1] - The acceptance number for the application is CYHS2503515, and it is classified as a Class 4 chemical drug [1] - The company will fulfill its information disclosure obligations in accordance with relevant regulations regarding subsequent developments [1] Group 2 - This matter is not expected to have a significant impact on the company's business operations in the short term [1]

Core Viewpoint - The company, Panlong Pharmaceutical (002864.SZ), has received a notice of acceptance for the marketing authorization application of its research product, Loxoprofen Sodium Gel Patch, from the National Medical Products Administration (NMPA) [1] Group 1: Product Information - Loxoprofen Sodium Gel Patch (PLJT-001) is designed to treat osteoarthritis, muscle pain, and swelling or pain after injuries [1] - The active ingredient, Loxoprofen Sodium, is a non-steroidal anti-inflammatory drug (NSAID) with significant anti-inflammatory and analgesic effects, particularly strong analgesic properties [1] - The mechanism of action involves the inhibition of prostaglandin synthesis, targeting cyclooxygenase [1] Group 2: Product Features - Loxoprofen Sodium is a prodrug that is absorbed through the skin and converted into an active metabolite, trans-OH, to exert its effects [1] - The gel patch is characterized by low irritation and allergenic potential, strong adhesion, and a lightweight formulation that allows for good skin extensibility [1] - It can be applied to active joints without affecting daily activities, significantly enhancing medication comfort and convenience [1]

Core Viewpoint - The company, Panlong Pharmaceutical (002864.SZ), has received a notice of acceptance for the marketing authorization application of its research product, Loxoprofen Sodium Gel Patch, from the National Medical Products Administration (NMPA) [1] Group 1: Product Information - Loxoprofen Sodium Gel Patch (PLJT-001) is designed to treat osteoarthritis, muscle pain, and swelling or pain following injuries [1] - The active ingredient, Loxoprofen Sodium, is a non-steroidal anti-inflammatory drug (NSAID) with significant anti-inflammatory and analgesic effects, particularly strong analgesic properties [1] - The mechanism of action involves the inhibition of prostaglandin synthesis, targeting cyclooxygenase [1] Group 2: Product Features - Loxoprofen Sodium is a prodrug that is absorbed through the skin and converted into the active metabolite trans-OH to exert its effects [1] - The gel patch is characterized by low irritation and allergenic potential, strong adhesion, and a lightweight formulation that allows for good skin extensibility [1] - It can be applied to active joints without affecting daily activities, significantly enhancing medication comfort and convenience [1]

Core Viewpoint - The company, Panlong Pharmaceutical, has received a notice from the National Medical Products Administration regarding the acceptance of its application for the marketing authorization of the generic drug, Loxoprofen Sodium Gel Patch, which is intended for the treatment of osteoarthritis, muscle pain, and swelling or pain from injuries [1] Group 1 - The Loxoprofen Sodium Gel Patch contains 100mg of Loxoprofen Sodium per patch, calculated as C15H17NaO3 [1] - Following the acceptance of the marketing authorization application, the product will undergo review and approval by the Drug Evaluation Center of the National Medical Products Administration, with completion time and approval results being uncertain [1]

Group 1 - The company, Panlong Pharmaceutical (002864), announced on September 24 that it plans to purchase a new building to serve as dedicated employee housing for its production base staff to address their accommodation needs [1]

Core Insights - The company, Panlong Pharmaceutical, plans to purchase 147 furnished apartments for employee accommodation, with a total transaction price exceeding its net profit for the first half of the year [1][2]. Financial Performance - For the first half of 2025, Panlong Pharmaceutical reported a revenue of 574 million yuan, a year-on-year increase of 26.06%, and a net profit of 60.14 million yuan, a year-on-year increase of 0.81% [1][4]. - The company also achieved a net profit excluding non-recurring items of 52.86 million yuan, reflecting a year-on-year growth of 4.19% [4]. Employee Welfare Initiatives - The acquisition of the "Bicuiyuan" project is aimed at improving the living conditions of employees and ensuring a stable workforce, which is deemed necessary and reasonable for the company's operations [3]. - The company emphasizes its commitment to employee welfare, stating that it aims to create a "spiritual home" for employees and ensure they lead good lives [1][5]. Company Background - Panlong Pharmaceutical was established in 1997 and listed on the Shenzhen Stock Exchange in November 2017, focusing on standardized planting of medicinal materials, drug production, research and development, sales, and pharmaceutical logistics [4]. - As of the end of 2024, the company had a total of 933 employees [4].

南财智讯9月20日电，盘龙药业公告，公司于2025年9月19日召开第五届董事会第一次会议，选举谢晓林 为董事长，审议通过了第五届董事会各专门委员会的组成，聘任张德柱为副总裁并代行总裁职务，吴杰 为董事会秘书，祝凤鸣为财务总监，孟重和黄继林为副总裁，赵晓妮为证券事务代表。上述人员均具备 相应任职资格，任期自第五届董事会第一次会议审议通过之日起至第五届董事会任期届满之日止。 ...

Group 1 - The core viewpoint of the article is that Panlong Pharmaceutical held its first board meeting of the fifth session on September 19, 2025, to discuss the appointment of the board secretary and other related documents [1] - For the first half of 2025, Panlong Pharmaceutical's revenue composition was as follows: pharmaceutical manufacturing and sales accounted for 99.34%, other products accounted for 0.52%, and health products accounted for 0.14% [1] - As of the report date, Panlong Pharmaceutical's market capitalization was 3.2 billion yuan [1]

证券代码：002864 证券简称：盘龙药业 公告编号：2025-046 陕西盘龙药业集团股份有限公司 关于购买资产暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关联交易概述 陕西盘龙药业集团股份有限公司（以下简称"公司"）为全力支持西渝高铁 项目建设，已按计划完成原有职工宿舍楼的拆除工作。为妥善解决生产基地员工 的住宿需求，切实改善员工生活与休息条件，为其营造更加安全、舒适的生活和 工作环境，公司现拟购置陕西嘉兴房地产开发有限公司（以下简称"嘉兴地产"） 开发的"碧翠苑"项目 5 号楼，作为专门的生产基地员工公寓。 本次交易对方嘉兴地产为公司控股股东、实际控制人谢晓林先生直接控股的 企业。根据《深圳证券交易所股票上市规则》的规定，本次交易构成关联交易。 公司于 2025 年 9 月 19 日召开第五届董事会第一次会议审议通过了《关于公 司购买资产暨关联交易的议案》，关联董事谢晓林、谢晓锋先生回避表决，本次 关联交易事项在提交董事会审议前已经公司 2025 年第二次独立董事专门会议审 议通过。本次交易金额及公司连续十二个月内与关联方累计已 ...